EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug
July 21, 2017 at 07:54 AM EDT
July 21 (Reuters) - European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.
